{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:41:43Z","timestamp":1793814103751,"version":"4.6.1"},"reference-count":43,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01 NS131912"],"award-info":[{"award-number":["R01 NS131912"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Overwhelming presence of immunoregulatory myeloid cells and dysfunctional T cells is a major barrier to effective immunotherapies in glioblastoma (GBM). Therapeutic strategies that simultaneously address myeloid-driven immunosuppression and impaired T cell function are therefore needed to restore antitumor immunity in GBM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We employed single-cell RNA sequencing, immunophenotyping, and functional analyses in an orthotopic murine GBM model (SB28) to investigate how hypoxia shapes the tumor immune microenvironment and limits CD8+ T cell responses. Pharmacologic hypoxia modulation using low-dose axitinib was combined with therapeutic intervention targeting CD137 in two GBM models (SB28, CT2A).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Monocyte-derived macrophages (MDMs) and neutrophils constitute the most abundant and functionally immunosuppressive myeloid subsets within the GBM TME. Hypoxia reprogrammed MDMs and neutrophils into immunosuppressive cells, limiting the expansion of CD8+ T cells. Low-dose axitinib reduced intratumoral hypoxia, leading to altered glucose uptake and histone lactylation in MDMs and neutrophils, thereby impairing their immunosuppressive function and promoting the expansion of intratumoral PD-1+CD137+CD8+ T cells, specifically in the SB28 model. CD137 is largely expressed by effector-like exhausted CD8+ T cell subsets (EX-eff). Agonistic targeting of CD137, in combination with axitinib, robustly expanded EX-eff, which was accompanied by durable tumor regression, immunological memory, and long-term survival. Additionally, the abundance of PD-1+CD137+CD8+ T cells correlated with improved disease-free survival in patients with GBM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Together, these findings establish a rationale for a combinatorial strategy that couples myeloid cells targeting and CD8+ T cell activation to overcome immunotherapy resistance in GBM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noag226","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:02:40Z","timestamp":1789473760000},"source":"Crossref","is-referenced-by-count":1,"title":["Targeting hypoxia-driven histone lactylation in myeloid cells synergizes with CD137 agonism to expand effector-like exhausted CD8+ T cells in glioblastoma"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5970-9693","authenticated-orcid":false,"given":"Alessio","family":"Ugolini","sequence":"first","affiliation":[{"name":"Genome Regulation and Cell Signaling Program, The Wistar Institute , Philadelphia, Pennsylvania,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6408-2055","authenticated-orcid":false,"given":"Fabio","family":"Scirocchi","sequence":"additional","affiliation":[{"name":"Department of Immunology, H. Lee Moffitt Cancer Center , Tampa, Florida,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3630-5765","authenticated-orcid":false,"given":"Alessandra","family":"De Leo","sequence":"additional","affiliation":[{"name":"Genome Regulation and Cell Signaling Program, The Wistar Institute , Philadelphia, Pennsylvania,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6232-5528","authenticated-orcid":false,"given":"Filippo","family":"Badii","sequence":"additional","affiliation":[{"name":"Genome Regulation and Cell Signaling Program, The Wistar Institute , Philadelphia, Pennsylvania,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxian","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatic, H. Lee Moffitt Cancer Center , Tampa, Florida,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2097-7874","authenticated-orcid":false,"given":"Angelica","family":"Pace","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, Sapienza University of Rome , Rome,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9182-1928","authenticated-orcid":false,"given":"Luca","family":"D\u2019Angelo","sequence":"additional","affiliation":[{"name":"Department of Human Neurosciences, Neurosurgery Division, \u201cSapienza\u201d University, AOU Policlinico Umberto I , Rome,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1907-7150","authenticated-orcid":false,"given":"James K C","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, H. Lee Moffitt Cancer Center , Tampa, Florida,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9656-4702","authenticated-orcid":false,"given":"Arnold B","family":"Etame","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, H. Lee Moffitt Cancer Center , Tampa, Florida,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pulak","family":"Ray","sequence":"additional","affiliation":[{"name":"Helen F. Graham Cancer Center and Research Institute, Christiana Care , Newark, Delaware,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Nuti","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, Sapienza University of Rome , Rome,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Santoro","sequence":"additional","affiliation":[{"name":"Department of Human Neurosciences, Neurosurgery Division, \u201cSapienza\u201d University, AOU Policlinico Umberto I , Rome,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1863-8251","authenticated-orcid":false,"given":"Aurelia","family":"Rughetti","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, Sapienza University of Rome , Rome,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9833-2374","authenticated-orcid":false,"given":"Michael A","family":"Vogelbaum","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, H. Lee Moffitt Cancer Center , Tampa, Florida,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatic, H. Lee Moffitt Cancer Center , Tampa, Florida,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6710-1584","authenticated-orcid":false,"given":"Filippo","family":"Veglia","sequence":"additional","affiliation":[{"name":"Genome Regulation and Cell Signaling Program, The Wistar Institute , Philadelphia, Pennsylvania,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"2026100806020331300_noag226-B1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"2026100806020331300_noag226-B2","doi-asserted-by":"publisher","first-page":"eads0449","DOI":"10.1126\/sciimmunol.ads0449","article-title":"The immunology of brain tumors","volume":"10","author":"Bunse","year":"2025","journal-title":"Sci Immunol"},{"key":"2026100806020331300_noag226-B3","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41577-025-01161-6","article-title":"The diversity of CD8(+) T cell dysfunction in cancer and viral infection","volume":"25","author":"Galluzzi","year":"2025","journal-title":"Nat Rev Immunol"},{"issue":":","key":"2026100806020331300_noag226-B4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/cells10010018","article-title":"Myeloid cells in Glioblastoma microenvironment","volume":"10","author":"De Leo","year":"2020","journal-title":"Cells"},{"key":"2026100806020331300_noag226-B5","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s41593-020-00789-y","article-title":"Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization","volume":"24","author":"Pombo Antunes","year":"2021","journal-title":"Nat Neurosci"},{"key":"2026100806020331300_noag226-B6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s43018-025-01097-9","article-title":"Immunosuppressive mechanisms and therapeutic interventions shaping glioblastoma immunity","volume":"7","author":"Moreno-Sanchez","year":"2026","journal-title":"Nat Cancer"},{"key":"2026100806020331300_noag226-B7","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.immuni.2024.04.006","article-title":"Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma","volume":"57","author":"De Leo","year":"2024","journal-title":"Immunity"},{"key":"2026100806020331300_noag226-B8","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1158\/2159-8290.CD-24-1056","article-title":"Functional reprogramming of neutrophils within the brain tumor microenvironment by Hypoxia-Driven histone lactylation","volume":"15","author":"Ugolini","year":"2025","journal-title":"Cancer Discov"},{"issue":":","key":"2026100806020331300_noag226-B9","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.3390\/cancers14051176","article-title":"Current understanding of Hypoxia in Glioblastoma Multiforme and its response to Immunotherapy","volume":"14","author":"Park","year":"2022","journal-title":"Cancers"},{"key":"2026100806020331300_noag226-B10","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.immuni.2023.06.017","article-title":"Hypoxic niches attract and sequester tumor-associated macrophages and cytotoxic T cells and reprogram them for immunosuppression","volume":"56","author":"Sattiraju","year":"2023","journal-title":"Immunity"},{"key":"2026100806020331300_noag226-B11","doi-asserted-by":"publisher","first-page":"5336","DOI":"10.1016\/j.cell.2024.07.030","article-title":"Macrophage-mediated myelin recycling fuels brain cancer malignancy","volume":"187","author":"Kloosterman","year":"2024","journal-title":"Cell"},{"key":"2026100806020331300_noag226-B12","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1158\/1078-0432.CCR-17-1846","article-title":"T-Cell exhaustion signatures vary with tumor type and are severe in glioblastoma","volume":"24","author":"Woroniecka","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026100806020331300_noag226-B13","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1158\/1078-0432.CCR-18-1176","article-title":"Expression of PD-1 by T cells in malignant glioma patients reflects exhaustion and activation","volume":"25","author":"Davidson","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2026100806020331300_noag226-B14","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1158\/2159-8290.CD-22-0869","article-title":"Sex-Biased T-cell exhaustion drives differential immune responses in glioblastoma","volume":"13","author":"Lee","year":"2023","journal-title":"Cancer Discov"},{"key":"2026100806020331300_noag226-B15","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/s41586-025-08633-8","article-title":"Programs, origins and immunomodulatory functions of myeloid cells in glioma","volume":"640","author":"Miller","year":"2025","journal-title":"Nature"},{"issue":":","key":"2026100806020331300_noag226-B16","doi-asserted-by":"publisher","first-page":"e002181","DOI":"10.1136\/jitc-2020-002181","article-title":"Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory Glioblastoma.","volume":"9","author":"Simonds","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026100806020331300_noag226-B17","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","article-title":"Intratumoral Tcf1(+)PD-1(+)CD8(+) T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy","volume":"50","author":"Siddiqui","year":"2019","journal-title":"Immunity"},{"key":"2026100806020331300_noag226-B18","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ccell.2025.12.004","article-title":"Antigen-specific profiling identifies T-bet(+) melanoma-specific CD8(+) T cells associated with response to neoadjuvant PD-1 blockade","volume":"44","author":"Wang","year":"2026","journal-title":"Cancer Cell"},{"key":"2026100806020331300_noag226-B19","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/s41590-021-00940-2","article-title":"Metabolic reprogramming of terminally exhausted CD8(+) T cells by IL-10 enhances anti-tumor immunity","volume":"22","author":"Guo","year":"2021","journal-title":"Nat Immunol"},{"key":"2026100806020331300_noag226-B20","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1126\/science.1229620","article-title":"Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection","volume":"338","author":"Paley","year":"2012","journal-title":"Science"},{"key":"2026100806020331300_noag226-B21","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat Immunol"},{"issue":":","key":"2026100806020331300_noag226-B22","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41577-025-01238-2","article-title":"Guidelines for T cell nomenclature","volume":"26","author":"Masopust","year":"2026","journal-title":"Nat Rev Immunol"},{"key":"2026100806020331300_noag226-B23","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1158\/2159-8290.CD-22-1029","article-title":"CD137 (4-1BB)-based cancer immunotherapy on its 25th anniversary","volume":"13","author":"Melero","year":"2023","journal-title":"Cancer Discov"},{"issue":":","key":"2026100806020331300_noag226-B24","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3390\/cancers13030456","article-title":"Cd137+ T-Cells: protagonists of the Immunotherapy revolution","volume":"13","author":"Ugolini","year":"2021","journal-title":"Cancers"},{"key":"2026100806020331300_noag226-B25","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nm0697-682","article-title":"Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors","volume":"3","author":"Melero","year":"1997","journal-title":"Nat Med"},{"key":"2026100806020331300_noag226-B26","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1158\/1078-0432.CCR-13-0945","article-title":"CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor","volume":"20","author":"Ye","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2026100806020331300_noag226-B27","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1158\/1078-0432.CCR-21-2918","article-title":"Circulating CD137+ T cells correlate with improved response to anti-PD1 immunotherapy in patients with cancer","volume":"28","author":"Zizzari","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026100806020331300_noag226-B28","doi-asserted-by":"publisher","first-page":"103098","DOI":"10.1016\/j.ebiom.2020.103098","article-title":"IgM-rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137(+)T-cells","volume":"62","author":"Ugolini","year":"2020","journal-title":"EBioMedicine"},{"key":"2026100806020331300_noag226-B29","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1158\/1078-0432.CCR-25-2502","article-title":"Safety, feasibility, and pharmacodynamic activity of intratumoral injections of the agonist anti-CD137 (4-1BB) mAb urelumab in combination with nivolumab","volume":"32","author":"Sanmamed","year":"2026","journal-title":"Clin Cancer Res"},{"key":"2026100806020331300_noag226-B30","doi-asserted-by":"publisher","first-page":"7279","DOI":"10.1038\/s41467-025-62263-2","article-title":"Polyclonal expansion of functional tumor-reactive lymphocytes infiltrating glioblastoma for personalized cell therapy","volume":"16","author":"Maffezzini","year":"2025","journal-title":"Nat Commun"},{"key":"2026100806020331300_noag226-B31","doi-asserted-by":"publisher","first-page":"103766","DOI":"10.1016\/j.xpro.2025.103766","article-title":"Protocol to study the genomic profile of histone lactylation with CUT&RUN assay in tumor-associated macrophages","volume":"6","author":"De Leo","year":"2025","journal-title":"STAR Protoc"},{"key":"2026100806020331300_noag226-B32","doi-asserted-by":"publisher","first-page":"e1501137","DOI":"10.1080\/2162402X.2018.1501137","article-title":"Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models","volume":"7","author":"Genoud","year":"2018","journal-title":"Oncoimmunology"},{"key":"2026100806020331300_noag226-B33","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"2026100806020331300_noag226-B34","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41590-022-01379-9","article-title":"Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity","volume":"24","author":"Vignali","year":"2023","journal-title":"Nat Immunol"},{"key":"2026100806020331300_noag226-B35","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174444","article-title":"Normalizing tumor vasculature to reduce hypoxia, enhance perfusion, and optimize therapy uptake","volume":"13","author":"Matuszewska","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026100806020331300_noag226-B36","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"2026100806020331300_noag226-B37","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.cell.2020.05.007","article-title":"Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells","volume":"181","author":"Klemm","year":"2020","journal-title":"Cell"},{"key":"2026100806020331300_noag226-B38","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.cell.2020.04.055","article-title":"Single-Cell mapping of human brain cancer reveals tumor-specific instruction of tissue-invading leukocytes","volume":"181","author":"Friebel","year":"2020","journal-title":"Cell"},{"key":"2026100806020331300_noag226-B39","doi-asserted-by":"publisher","first-page":"4546","DOI":"10.1016\/j.cell.2023.08.043","article-title":"The local microenvironment drives activation of neutrophils in human brain tumors","volume":"186","author":"Maas","year":"2023","journal-title":"Cell"},{"key":"2026100806020331300_noag226-B40","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1038\/s41467-020-17704-5","article-title":"Immune phenotyping of diverse syngeneic murine brain tumors identifies immunologically distinct types","volume":"11","author":"Khalsa","year":"2020","journal-title":"Nat Commun"},{"key":"2026100806020331300_noag226-B41","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/s41467-021-21407-w","article-title":"Single-cell RNA sequencing reveals functional heterogeneity of glioma-associated brain macrophages","volume":"12","author":"Ochocka","year":"2021","journal-title":"Nat Commun"},{"issue":":e192658.","key":"2026100806020331300_noag226-B42","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.192658","article-title":"Tumor heterogeneity underlies clinical outcome and MEK inhibitor response in somatic NF1-mutant glioblastoma","volume":"10","author":"Pan","year":"2025","journal-title":"JCI Insight"},{"key":"2026100806020331300_noag226-B43","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s00262-018-2136-x","article-title":"The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models","volume":"67","author":"Laubli","year":"2018","journal-title":"Cancer Immunol Immunother"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noag226\/71656793\/noag226.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noag226\/71656793\/noag226.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T10:02:10Z","timestamp":1791453730000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article\/doi\/10.1093\/neuonc\/noag226\/8874082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":43,"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noag226","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"article-number":"noag226"}}